Physician profile
Beth A Yoder
NPI 1689771255
$2,453.01
in general payments reported to CMS, 2019-2025
17 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $479 · 2020: $247 · 2021: $412 · 2022: $324 · 2023: $601 · 2024: $269 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $933 · Entertainment: $58.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $932.65 |
| Entertainment | $58.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,098.36 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $321.10 | 2019-2025 | Total30, Precision7 |
| Optos, INC. | $217.02 | 2021-2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $142.26 | 2019-2021 | |
| Biotissue Holdings INC. | $113.91 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $99.56 | 2022-2025 | Infuse, Xiidra |
| Abb Con-Cise Optical Group LLC | $91.76 | 2019 | |
| Sun Pharmaceutical Industries INC. | $88.13 | 2020 | |
| Carl Zeiss Meditec, INC. | $51.72 | 2019 | |
| Novartis Pharmaceuticals Corporation | $49.79 | 2023 | |
| Coopervision INC. | $45.27 | 2022-2024 | Myday Contact Lens |
| Ivantis, INC | $38.46 | 2019 | |
| Sight Sciences, INC. | $36.67 | 2022 | |
| Allergan, INC. | $19.66 | 2021 | |
| Kala Pharmaceuticals, INC. | $15.19 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lkc Technologies, INC. | $14.36 | 2025 | |
| Glaxosmithkline, LLC. | $9.79 | 2023 | Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Yoder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.